Chen et al. investigated the potential mechanism behind LRP1B mutation and immune response in melanoma and NSCLC and found that cell cycle and antigen processing pathways were significantly altered in samples with LRP1B mutation, and patients with LRP1B mutation had higher T cell inflamed gene expression profiling scores [37]. Here, LRP1B is linked to melanoma.